Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Interest Coverage 10.60
COV's Interest Coverage is ranked lower than
58% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.66 vs. COV: 10.60 )
Ranked among companies with meaningful Interest Coverage only.
COV' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 10.6
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
» COV's 10-Y Financials

Financials (Next Earnings Date: 0)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

COV Guru Trades in Q2 2014

George Soros 227,000 sh (New)
John Paulson 7,000,000 sh (New)
Eric Mindich 446,000 sh (New)
Louis Moore Bacon 126,022 sh (+1992.69%)
Jeremy Grantham 2,776,488 sh (+31.99%)
Mario Gabelli 637,530 sh (+17.29%)
Ronald Muhlenkamp 182,180 sh (+0.40%)
HOTCHKIS & WILEY 788,700 sh (+0.04%)
First Eagle Investment 1,500 sh (unchged)
Vanguard Health Care Fund 4,994,700 sh (unchged)
Yacktman Fund Sold Out
Yacktman Focused Fund Sold Out
Robert Olstein Sold Out
Manning & Napier Advisors, Inc Sold Out
Donald Yacktman Sold Out
Joel Greenblatt Sold Out
Ray Dalio Sold Out
Private Capital 238,715 sh (-2.09%)
Steven Romick 4,559,929 sh (-6.01%)
John Keeley 40,840 sh (-6.69%)
First Pacific Advisors 4,822,800 sh (-6.98%)
Dodge & Cox 92,017 sh (-9.36%)
Pioneer Investments 1,818,973 sh (-41.91%)
Bill Nygren 160,000 sh (-94.09%)
Paul Tudor Jones 7,416 sh (-97.44%)
» More
Q3 2014

COV Guru Trades in Q3 2014

David Abrams 2,620,000 sh (New)
Paul Singer 502,653 sh (New)
Steven Cohen 45,000 sh (New)
Eric Mindich 3,881,000 sh (+770.18%)
Jeremy Grantham 12,981,012 sh (+367.53%)
John Paulson 12,595,000 sh (+79.93%)
Ronald Muhlenkamp 182,180 sh (unchged)
Pioneer Investments 1,770,893 sh (unchged)
Steven Romick 4,559,929 sh (unchged)
Vanguard Health Care Fund 4,994,700 sh (unchged)
Bill Nygren 160,000 sh (unchged)
John Keeley 40,840 sh (unchged)
First Eagle Investment 1,500 sh (unchged)
George Soros Sold Out
Louis Moore Bacon Sold Out
First Pacific Advisors 4,774,600 sh (-1.00%)
Dodge & Cox 89,017 sh (-3.26%)
HOTCHKIS & WILEY 727,700 sh (-7.73%)
Mario Gabelli 462,251 sh (-27.49%)
Private Capital 157,828 sh (-33.88%)
Paul Tudor Jones 3,900 sh (-47.41%)
» More
Q4 2014

COV Guru Trades in Q4 2014

David Einhorn 851,341 sh (New)
John Burbank 5,094 sh (New)
George Soros 197,768 sh (New)
Eric Mindich 5,481,800 sh (+41.25%)
HOTCHKIS & WILEY 935,100 sh (+28.50%)
Pioneer Investments 2,008,046 sh (+13.39%)
David Abrams 2,950,000 sh (+12.60%)
Steven Cohen 50,000 sh (+11.11%)
Steven Romick 4,651,129 sh (+2.00%)
First Pacific Advisors 4,861,900 sh (+1.83%)
John Keeley 40,860 sh (+0.05%)
Vanguard Health Care Fund 4,994,700 sh (unchged)
First Eagle Investment 1,500 sh (unchged)
Bill Nygren Sold Out
Paul Tudor Jones Sold Out
Paul Singer Sold Out
Ronald Muhlenkamp 181,650 sh (-0.29%)
Private Capital 152,848 sh (-3.16%)
Dodge & Cox 78,686 sh (-11.61%)
John Paulson 10,047,500 sh (-20.23%)
Mario Gabelli 359,176 sh (-22.30%)
Jeremy Grantham 9,819,037 sh (-24.36%)
» More
Q1 2015

COV Guru Trades in Q1 2015

John Burbank Sold Out
David Abrams Sold Out
Ronald Muhlenkamp Sold Out
Pioneer Investments Sold Out
First Eagle Investment Sold Out
Mario Gabelli Sold Out
Vanguard Health Care Fund Sold Out
Steven Romick Sold Out
Jeremy Grantham Sold Out
Dodge & Cox Sold Out
George Soros Sold Out
John Paulson Sold Out
Steven Cohen Sold Out
David Einhorn Sold Out
Private Capital Sold Out
Eric Mindich Sold Out
HOTCHKIS & WILEY Sold Out
John Keeley Sold Out
First Pacific Advisors Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with COV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.30
COV's Dividend Yield is ranked lower than
52% of the 141 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.34 vs. COV: 1.30 )
Ranked among companies with meaningful Dividend Yield only.
COV' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 1.3
Current: 1.3
0
1.3
Dividend Payout 0.43
COV's Dividend Payout is ranked lower than
56% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.38 vs. COV: 0.43 )
Ranked among companies with meaningful Dividend Payout only.
COV' s Dividend Payout Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 0.43
Yield on cost (5-Year) 1.30
COV's Yield on cost (5-Year) is ranked higher than
67% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.73 vs. COV: 1.30 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
COV' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 1.3
Current: 1.3
0
1.3

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue(Mil) $10706
EPS $ 3.89
Short Percentage of Float0.35%
52-Week Range $65.97 - 108.57
Shares Outstanding(Mil)452.78

Analyst Estimate

Sep15 Sep16 Sep17
Revenue(Mil) 10,979 11,379 11,923
EPS($) 4.31 4.69 4.64
EPS without NRI($) 4.31 4.69 4.64

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NYSE:BDX, XPAR:EINV, NAS:ILMN, NYSE:BAX, OCSE:COLO B » details
Traded in other countries:6COP.Germany,
Covidien PLC formerly known as Covidien Ltd. was incorporated in Bermuda in 2000 as a wholly-owned subsidiary of Tyco International Ltd. In June 2009, Covidien plc announced that one of its subsidiaries has completed the acquisition of VNUS Medical Technologies, Inc. In September 2009, the Company completed the acquisition of Power Medical Interventions Inc. In November 2009, the Company completed the acquisition of Aspect Medical Systems Inc. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. Its products are found in almost every hospital in the United States. Its mission is to create and deliver innovative healthcare solutions, developed in ethical collaboration with medical professionals. It operates through two segments: Medical Devices and Medical Supplies. The Medical Devices segment includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products, and other medical products. The Medical Supplies segment includes the development, manufacture and sale of nursing care products, medical surgical products, SharpSafety products and original equipment manufacturer products. Competitors of Medical Devices segment include diversified healthcare companies, such as Johnson & Johnson, Boston Scientific, Baxter and C.R. Bard. Its Nursing Care products include: Curity and Kerlix and Medical Surgical products include: Medi-Trace. The Company holds more than 13,000 patents and have over 10,500 patent applications pending in the United States and in certain other countries that relate to aspects of the technology used in many of its products. The Company is subject to numerous federal, state and local environmental protection and health and safety laws and regulations both within and outside the United States.
» More Articles for COV

Headlines

Articles On GuruFocus.com
Medtronic Continues to Report Solid Numbers Dec 04 2015 
Mairs & Power Balanced Fund Q4 2014 Commentary Mar 31 2015 
Weekly 52-Week Highs Highlight: KR, COV, VRX, NOC Feb 01 2015 
Dravid Abrams and His Top Four Stock Picks Jan 27 2015 
Johnson & Johnson Riding High On Ebola Vaccines Jan 21 2015 
I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
Dividend Aristocrats In Focus Part 44: Medtronic Nov 23 2014 
Third Avenue's Top Stocks as of Q3 Nov 16 2014 
Medical Technology Company Offers Investment Opportunity Sep 25 2014 
Gabelli Value 25 Fund Second Quarter Commentary Sep 15 2014 

More From Other Websites
What’s Medtronic’s Plan to Use Its Increased Cash Accessibility? Apr 08 2016
Medtronic Earnings: Recently Launched Products And Covidien Revenues Help Post Strong Quarter Mar 02 2016
Medtronic Is Buying Its Way to Better Stock Health Feb 29 2016
Medtronic (MDT) to Report Q3 Earnings: What's in the Cards? Feb 25 2016
Tyco's Tax Avoidance Machine Will Outlive Its Infamous Name Jan 25 2016
Medtronic releases plan for spending $9.3B in freed cash Jan 11 2016
Medtronic PLC (MDT): Double-Digit Dividend Growth for this Dividend Aristocrat Dec 16 2015
Medtronic's Covidien deal freed up $9.3B in cash. Now, how to spend it? Dec 03 2015
Dividend Aristocrats Part 27: Medtronic PLC (MDT) Dec 03 2015
Medtronic's Overseas Tax Move Freed Up $9.3 Billion Dec 03 2015
Medtronic Beats Q2 Earnings, Covidien Integration on Track Dec 03 2015
Medtronic Notches Strong Quarter Despite FX Headwinds Dec 03 2015
Medical device maker Medtronic's profit beats estimates Dec 03 2015
U.S. top court rejects Covidien bid to restore patent verdict against Ethicon Nov 30 2015
Baxter names former Covidien chief José Almeida CEO Oct 28 2015
Medtronic: Balanced Growth in Q1, Covidien Synergy on Track Sep 07 2015
Is There Another 25% Upside in Medtronic? Sep 04 2015
Medtronic sales surge as rise in U.S. surgeries drives demand Sep 03 2015
Medtronic Beats on Q1 Earnings, Covidien Synergy on Track Sep 03 2015
Medtronic (MDT) Stock Rallies as Earnings Exceed Estimates, Jim Cramer Weighs In Sep 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK